OakChart

VolitionRX Ltd

VNRXHealthcare·Medical Devices·USA·Nano·AMEX·Nov 11 • 3:59 PM ET

0.2036+0.0192 (10.41%)
2026-11-12 05:47 CET
Market cap
5.68 USD m
Revenue, TTM
2.46 USD m
Net income, TTM
-26.10 USD m
Free cash flow, TTM
-18.86 USD m
EPS diluted, TTM
-3.84
P/E
-
Compare

Price

VNRX against its 20, 50 and 200-day averages
2050200missearnings
0.002.004.006.00177.1M354.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VNRXclose 0.2020-day 0.1950-day 0.24200-day 1.940.20

97.5% under the 52-week high of 8.13 on 12 Nov 2025. 52-week low 0.16 on 22 Oct 2026. Last 15 sessions, 41.0% high to low

Volume 0.08× normal · the line is the 50-bar volume average

Profile

VNRX
52-week range, 1% of the way up
0.168.13

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Employees75
IPOApr 25, 2007
Beta1.16
ATR, 14d0.02
Rel volume0.08
Short float5.26%
Insider own4.77%
Inst own7.70%

Snapshot

6 groups

Valuation

Index-
Market Cap5.69M
Enterprise Value12.94M
Income-26.10M
Sales2.46M
Book/sh-2.67
Cash/sh0.10
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees75
IPOApr 25, 2007

Ratios

P/E-
Forward P/E-
PEG-
P/S2.31
P/B-
P/C2.04
P/FCF-
EV/EBITDA-
EV/Sales5.26
Quick Ratio0.30
Current Ratio0.30
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.84
EPS next Y-0.73
EPS next Q-0.38
EPS this Y55.97%
EPS next Y62.15%
EPS next 5Y57.20%
EPS past 3/5Y26.33% 13.42%
Sales past 3/5Y77.98% 164.15%
EPS Y/Y TTM21.31%
Sales Y/Y TTM86.32%
EPS Q/Q30.54%
Sales Q/Q-1.97%
EarningsNov 13 BMO
EPS/Sales Surpr.-49.78% -4.00%

Ownership

Insider Own4.77%
Insider Trans0.00%
Inst Own7.70%
Inst Trans1.07%
ROA-306.96%
ROE-
ROIC-
Gross Margin53.07%
Oper. Margin-790.23%
Profit Margin-1061.82%
SMA208.80%
SMA50-13.58%
SMA200-89.53%
Trades-

Technical

Shs Outstand27.90M
Shs Float26.57M
Short Float5.26%
Short Ratio0.17
Short Interest1.40M
52W High8.13 -97.49%
52W Low0.16 30.18%
Volatility10.50% 9.86%
ATR (14)0.02
RSI (14)47.20
Beta1.16
Rel Volume0.08
Avg Volume8.46M
Volume681,852

Performance

Perf Week0.25%
Perf Month10.23%
Perf Quarter-67.71%
Perf Half Y-91.37%
Perf YTD-96.02%
Perf Year-97.32%
Perf 3Y-98.84%
Perf 5Y-99.72%
Perf 10Y-99.76%
Recom1.67
Target Price8.04
Prev Close0.18
Price0.20
Change %10.41%

Analyst ratings

latest 8 of 8
DateActionAnalystRating changeTargetImplied
Apr 08, 2025InitiatedHH.C. WainwrightBuy$2.50+1,127.9%
Feb 01, 2023DowngradeTThe Benchmark CompanyBuy → Hold
Feb 17, 2022ResumedCCantor FitzgeraldOverweight$8 → $7+3,338.1%
Mar 10, 2021InitiatedCCantor FitzgeraldOverweight$8+3,829.3%
May 16, 2018InitiatedMMaxim GroupBuy$6+2,847.0%
May 14, 2018ReiteratedTThe Benchmark CompanyBuy$7 → $5+2,355.8%
Sep 07, 2016ReiteratedRRodman & RenshawBuy$12 → $10+4,811.6%
Feb 01, 2016InitiatedRRodman & RenshawBuy$12+5,793.9%

Peers

Mkt cap
TickerCompanyMkt cap
AIDX20/20 Biolabs Inc3.00M
BIAFBioAffinity Technologies Inc4.41M
LUCDLucid Diagnostics Inc77.52M
MDXHMDxHealth SA13.98M
GHGuardant Health Inc20.94B
FRNMFreenome Inc1.24B
BDSXBiodesix Inc112.22M
PRPOPrecipio Inc44.40M
XGNExagen Inc121.98M
OPKOpko Health Inc1.27B

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Reynolds Cameron JohnPresident and CEONov 17 '25Buy0.3520,0007,0002,554,847Nov 17 01:12 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • VolitionRx Needs Revenue Rebound And Inked Licensing Deals As Cash Runway And Stock Shrink (Earnings Whispers) -7.80%
  • VolitionRx Limited Schedules Third Quarter 2026 Earnings Conference Call and Business Update (PR Newswire)
  • VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide (PR Newswire)
  • VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash (PR Newswire)
  • VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France (PR Newswire)
  • VolitionRx Participates in Launch of DETECSEPS Program in France (PR Newswire)
  • VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027 (PR Newswire)
  • Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference (PR Newswire)
  • VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets (PR Newswire) -11.80%
  • Volition Announces Landmark Clinical Validation of Nu.Q NETs Biomarker in Sepsis (PR Newswire)
  • VolitionRX: Q2 Earnings Snapshot (Associated Press) -5.68% -14.78%
  • VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update (PR Newswire)
  • Earnings To Watch: VolitionRX Ltd (VNRX) Q2 2026 -- GF Value Sees 3914% Upside (GuruFocus.com)
  • Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients (PR Newswire) -6.52%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-13--0.375--0.714
2026Q22026-08-13-0.850-0.568-0.8500.400.424
2026Q12026-05-14-0.970-0.730-0.9680.991.525
2025Q42026-03-31-1.010-0.833-1.0260.420.756
2025Q32025-11-13-1.000-0.880-0.9940.631.685
2025Q22025-08-15-1.200-1.080-1.2240.400.425
2025Q12025-05-15-1.200-0.864-1.1240.250.925
2024Q42025-03-31-1.050-1.100-1.2060.190.664
2024Q32024-11-14-1.400-1.450-1.3250.480.654
2024Q22024-08-14-1.702-1.880-1.6900.400.465
2024Q12024-05-13-2.000-2.000-2.0420.170.594
2023Q42024-03-25-2.000-2.066-2.1430.240.473
2023Q32023-11-14-2.200-2.560-2.1410.170.365
2023Q22023-08-14-2.800-2.866-2.8320.220.273
2023Q12023-05-10-3.000-2.800-2.9180.150.424
2022Q42023-03-15-2.600-2.920-2.5030.120.185

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-8.200-8.900-8.2180.020.02
2020FY-9.000-8.800-8.9900.010.01
2021FY-10.200-9.960-10.1850.090.10
2022FY-11.000-11.400-10.9370.310.37
2023FY-10.000-9.266-9.9160.781.03
2024FY-6.200-6.100-6.2331.231.46
2025FY-4.390-4.167-4.4001.701.75
2026FY--1.938--2.41
2027FY--0.733--3.86
2028FY--0.345--10.19
2029FY-0.370--30.79
2030FY-0.710--52.97

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-284100.710.461.16
2026Q3S2026-09-204300.710.461.16
2026Q3S2026-09-154310.710.461.16
2026Q3S2026-09-114310.710.461.16
2026Q3S2026-08-233210.550.460.60
2026Q3S2026-08-154010.400.200.58
2026Q3S2026-08-144210.500.350.60
2026Q3S2026-08-054020.400.200.58
2026Q3S2026-07-295020.490.200.85
2026Q3S2026-07-105030.490.200.85
2026Q3S2026-07-076030.520.200.85
2026Q3S2026-06-176020.530.200.85
2026Q3S2026-06-155020.530.200.85
2026Q3S2026-06-125030.530.200.85

Estimate history

EPS, annual-11.2-11.4-8.218-8.99-10.185-10.937-9.916-6.233-4.373-3.8391
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.69-1.325-1.206-1.124-1.224-0.994-1.026-0.968-0.851
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000.0170.0130.090.3060.7751.2341.7272.46
Period201720182019202020212022202320242025TTM
Sales, quarterly0.3960.4750.1920.2460.4070.6270.4470.9850.399
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual1.3261.7672.0562.432.6892.8944.0954.8056.28912.044
Period201720182019202020212022202320242025MRQ
Shares, quarterly4.1464.624.8055.0375.1995.4816.2897.93112.044
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue2.461.731.230.780.310.090.010.020.00
Cost of Goods Sold Incl. D&A1.151.241.301.411.19---0.64
Gross Profit1.300.49-0.07-0.64-0.88----0.64
Selling, General and Administrative Excl. Other20.7322.2326.9635.3530.9027.2820.2215.1617.26
Research and Development8.459.0513.3218.4313.7314.5713.689.6710.30
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-19.42-21.74-27.02-35.99-31.78-28.33-21.25-16.04-17.90
Interest Expense3.672.490.340.220.170.160.130.130.11
Unusual Expense3.04-0.21-0.03-0.240.000.000.00--
Net Income Before Taxes-25.73-23.50-27.26-35.68-30.60-26.99-20.40-16.10-18.01
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-26.19-23.50-27.26-35.68-30.60-26.99-20.40-16.10-18.01
Net Income From Continuing Operations-26.10-23.36-26.97-35.32-30.27-26.81-20.35-16.10-18.01
Net Income-26.10-23.36-26.97-35.32-30.27-26.81-20.35-16.10-18.01
EPS (Recurring)-2.62-4.40-6.24-9.96-10.94-10.18-8.99-8.22-11.47
EPS (Basic, Before Extraordinaries)-3.84-4.37-6.23-9.92-10.94-10.18-8.99-8.22-11.40
EPS (Diluted)-3.84-4.37-6.23-9.92-10.94-10.18-8.99-8.22-11.40
EBITDA-18.27-20.50-25.72-34.58-30.59-27.19-20.21-15.14-17.26
Non-Operating Income (Expense)0.400.520.080.291.351.500.980.070.00
Other After Tax Adjustments-0.460.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-1.741.272.293.113.580.971.021.80
Price To Sales Ratio5.0315.8142.0965.88438.981,836.3913,112.0910,863.06-
Gross Margin53.0728.19-5.57-82.07-287.88----
Operating Margin-790.23-1,258.47-2,190.90-4,641.76-10,372.36-31,468.96-158,176.25-93,840.22-
Net Margin-1,061.82-1,352.16-2,186.27-4,555.53-9,879.11-29,782.49-151,508.34-94,168.55-
Shares Outstanding12.046.294.804.092.892.692.432.061.77
Market Capitalization5.685.6857.6656.17139.72168.84189.08194.9363.96

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.400.990.450.630.410.250.190.47
Cost of Goods Sold Incl. D&A0.290.250.300.310.320.310.320.33
Gross Profit0.110.730.140.320.09-0.06-0.130.14
Selling, General and Administrative Excl. Other4.276.084.965.426.395.465.656.01
Research and Development1.592.622.222.022.462.352.323.19
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.16-5.35-4.82-5.10-6.30-5.52-5.78-5.87
Interest Expense1.150.581.070.870.450.100.090.09
Unusual Expense1.970.900.50-0.33-0.36-0.020.00-0.00
Net Income Before Taxes-7.32-6.70-6.30-5.41-6.31-5.48-5.86-5.87
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-7.78-6.70-6.30-5.41-6.31-5.48-5.86-5.87
Net Income From Continuing Operations-7.79-6.66-6.27-5.38-6.28-5.42-5.79-5.82
Net Income-7.79-6.66-6.27-5.38-6.28-5.42-5.79-5.82
EPS (Recurring)-0.70-0.88-0.97-1.04-1.27-1.13-1.21-1.33
EPS (Basic, Before Extraordinaries)-0.85-0.97-1.03-0.99-1.22-1.12-1.21-1.32
EPS (Diluted)-0.85-0.97-1.03-0.99-1.22-1.12-1.21-1.32
EBITDA-3.87-5.09-4.51-4.79-5.98-5.21-5.46-5.54
Non-Operating Income (Expense)-0.050.120.090.230.080.120.020.08
Other After Tax Adjustments-0.460.000.000.000.000.000.000.00
Stock Option Compensation Expense0.240.22-0.610.810.450.330.32
Price To Sales Ratio5.0311.2818.0849.9059.1442.0646.7441.08
Gross Margin28.3774.1731.8750.7421.67-25.12-68.9929.86
Operating Margin-1,042.50-542.99-1,077.86-813.20-1,548.56-2,241.09-3,016.50-1,236.76
Net Margin-1,953.09-676.57-1,402.76-857.41-1,545.18-2,201.33-3,022.78-1,226.82
Shares Outstanding12.047.936.295.485.205.044.804.62
Market Capitalization5.6832.0432.1574.4179.0357.4457.6655.53

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1.123.2620.7310.8720.5819.4416.9713.4310.12
Short Term Receivables0.320.110.240.070.010.010.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.630.680.881.231.390.880.590.480.45
Total Current Assets2.064.0621.8512.1721.9820.3317.5613.9010.57
Net Property, Plant & Equipment4.525.036.076.015.295.503.363.123.48
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.320.310.020.110.220.320.370.470.58
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets6.909.4027.9518.3027.4926.1521.2917.4914.62
Short Term Debt Incl. Current Port. of LT Debt3.611.131.451.361.021.081.000.560.58
Accounts Payable2.922.773.213.041.541.540.630.810.35
Other Current Liabilities5.703.9027.1712.993.963.622.230.961.36
Total Current Liabilities12.237.7931.8417.396.526.243.862.332.29
Long Term Debt7.854.694.403.623.003.362.932.702.19
Provision for Risks Charges0.000.000.000.000.000.000.00--
Other Liabilities21.9422.660.000.000.000.000.000.000.00
Total Liabilities42.0235.1536.2421.009.529.606.795.044.48
Non-Equity Reserves0.470.360.420.420.250.260.300.310.19
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-34.25-24.91-7.80-2.5717.9416.3414.2012.149.96
Total Shareholders Equity-34.25-24.91-7.80-2.5717.9416.3414.2012.149.96
Accumulated Minority Interest-1.35-1.20-0.91-0.55-0.22-0.050.000.000.00
Total Equity-35.59-26.11-8.71-3.1317.7216.2914.2012.149.96
Total Liabilities & Stockholders Equity6.909.4027.9518.3027.4926.1521.2917.4914.62
Book Value Per Share-5.45-5.18-1.91-0.896.676.726.916.877.51
Tangible Book Value Per Share-5.50-5.25-1.91-0.936.596.596.726.617.08
Full-Time Employees75851101048365504437
Price to Book Ratio-0.08-2.31-27.5042.379.4111.5713.735.275.82
Return on Assets-286.58-144.41-152.75-132.22-99.98-85.80-83.03-112.16-75.05
Return on Equity----393.88-156.42-133.28-122.24-162.99-94.88
Return on Invested Capital----2,909.14-128.03-103.30-93.96-121.31-121.60
Quick Ratio0.170.520.690.703.373.264.555.964.61
Current Ratio0.170.520.690.703.373.264.555.964.61

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-24.86-23.50-27.26-35.68-30.60-26.99-20.40-16.10-18.01
Depreciation1.091.221.341.411.191.151.040.900.64
Other Funds (Non Cash)6.903.491.272.073.115.151.431.662.59
Funds from Operations-16.87-18.80-24.64-32.20-26.29-20.70-17.93-13.53-14.78
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.97-0.89-1.2514.1411.02-0.161.460.790.05
Cash from Operating Activities-18.84-19.68-25.89-18.06-15.28-20.85-16.46-12.74-14.73
Capital Expenditures-0.02-0.09-0.57-1.08-1.57-0.97-1.94-0.51-0.30
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.290.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.02-0.09-0.57-1.08-1.57-0.97-1.65-0.51-0.30
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock18.9011.178.5928.366.7423.2221.1416.5917.25
Repurchase of Common Pref Stock0.000.000.00-0.030.000.00-0.050.000.00
Sale of Common Pref Stock18.9011.178.5928.396.7423.2221.2016.5917.25
Proceedsfrom Stock Options18.9011.178.5928.396.7423.2221.2016.5917.25
Issuance or Reduction of Debt, Net0.846.020.230.830.21-0.22-0.300.340.59
Change in Long Term Debt0.846.020.230.830.21-0.22-0.300.340.59
Issuance of Long Term Debt2.827.781.371.851.520.590.350.841.16
Reduction of Long Term Debt-1.98-1.76-1.14-1.03-1.31-0.81-0.64-0.49-0.57
Net Financing Active Other Cash Flow-0.08-0.10-0.17-0.20-0.01-0.14-0.22-0.010.14
Other Financing Activities Uses-0.15-0.21-0.17-0.23-0.23-0.18-0.23-0.04-0.04
Cash from Financing Activities19.6717.098.6628.986.9422.8620.6216.9317.97
Exchange Rate Effect-0.240.530.340.030.200.11-0.03-0.140.38
Net Change in Cash0.57-2.15-17.479.86-9.711.142.483.543.31
Free Cash Flow-18.86-19.77-26.17-19.15-16.85-21.83-18.41-13.25-15.03
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments2.793.101.120.202.262.60
Short Term Receivables0.280.250.320.310.190.19
Inventories0.000.000.000.000.000.00
Other Current Assets1.021.160.630.820.820.51
Total Current Assets4.094.522.061.333.263.29
Net Property, Plant & Equipment3.904.204.524.825.144.91
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.310.320.320.300.310.32
Other Assets0.000.000.000.000.000.00
Total Assets8.309.046.906.458.708.52
Short Term Debt Incl. Current Port. of LT Debt4.754.563.612.751.491.14
Accounts Payable3.563.722.923.112.353.01
Other Current Liabilities5.185.285.705.565.404.12
Total Current Liabilities13.4913.5712.2311.429.248.27
Long Term Debt6.667.147.858.519.456.23
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities21.2321.2321.9422.0322.6622.66
Total Liabilities41.3841.9342.0241.9641.3637.17
Non-Equity Reserves0.460.460.470.440.440.38
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-32.16-31.97-34.25-34.64-31.82-27.77
Total Shareholders Equity-32.16-31.97-34.25-34.64-31.82-27.77
Accumulated Minority Interest-1.37-1.39-1.35-1.31-1.28-1.25
Total Equity-33.54-33.36-35.59-35.95-33.10-29.03
Total Liabilities & Stockholders Equity8.309.046.906.458.708.52
Book Value Per Share-2.67-4.03-5.45-6.32-6.12-5.51
Tangible Book Value Per Share-2.70-4.07-5.50-6.37-6.18-5.58
Full-Time Employees--75---
Price to Book Ratio-0.08-1.00-0.94-2.15-2.48-2.07
Return on Assets-306.96-280.22-286.58-239.21-214.24-171.88
Quick Ratio0.300.330.170.120.350.40
Current Ratio0.300.330.170.120.350.40

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-7.09-6.70-5.83-5.24-6.49-5.48
Depreciation0.280.250.260.300.330.31
Other Funds (Non Cash)3.141.571.200.990.800.43
Funds from Operations-3.68-4.87-4.37-3.95-5.36-4.74
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.31-0.41-0.720.47-1.060.44
Cash from Operating Activities-4.99-5.28-5.09-3.48-6.42-4.30
Capital Expenditures-0.00-0.01-0.010.00-0.08-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.00-0.01-0.010.00-0.08-0.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock5.275.176.491.970.102.38
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock5.275.176.491.970.102.38
Proceedsfrom Stock Options5.275.176.491.970.102.38
Issuance or Reduction of Debt, Net-0.482.46-0.71-0.435.731.31
Change in Long Term Debt-0.482.46-0.71-0.435.731.31
Issuance of Long Term Debt-0.042.720.28-0.145.911.57
Reduction of Long Term Debt-0.43-0.26-0.99-0.29-0.18-0.26
Net Financing Active Other Cash Flow-0.01-0.020.03-0.08-0.02-0.02
Other Financing Activities Uses-0.01-0.02-0.05-0.08-0.06-0.02
Cash from Financing Activities4.787.625.811.465.813.67
Exchange Rate Effect-0.12-0.340.25-0.030.33-0.03
Net Change in Cash-0.341.990.96-2.04-0.36-0.66
Free Cash Flow-4.99-5.29-5.10-3.47-6.50-4.30

Revenue breakdown

In Vitro & In Vivo Diagnostic Substances2024: 1.23M 2025: 1.73M
United States2024: 1.23M 2025: 1.73M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.26%1.4M26.6M8.57M
2026-10-154.31%1.1M26.6M8.42M
2026-09-304.75%1.2M25.2M8.29M
2026-09-153.99%1.0M25.2M7.69M
2026-08-3118.30%2.2M12.2M7.38M
2026-08-145.63%0.7M12.2M515.10K
2026-07-315.25%0.5M10.3M309.38K
2026-07-152.61%0.3M10.3M289.02K
2026-06-304.28%0.3M7.5M289.93K
2026-06-153.51%0.3M7.3M678.35K
2026-05-295.42%0.4M7.2M625.23K
2026-05-156.06%0.4M6.9M598.70K
2026-04-304.14%0.3M6.5M570.91K
2026-04-155.56%0.4M6.4M565.81K
2026-03-316.33%0.4M6.4M551.90K
2026-03-131.25%0.1M5.5M110.53K
2026-02-271.30%0.1M5.5M111.01K
2026-02-132.10%0.1M5.5M127.81K
2026-01-301.51%0.1M5.2M116.99K
2026-01-151.15%0.1M4.9M106.91K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.500.009.4170.000.000.161-0.0040.000
call5.000.000.600.0011.8000.000.000.202-0.0060.000
call7.500.000.050.0515.5800.001.000.390-0.0100.000
put2.502.252.402.3517.19117.000.00-0.839-0.0040.000
put5.004.704.904.7719.0163.003.00-0.798-0.0050.000
put7.507.207.407.4020.1120.002.00-0.624-0.0090.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-278-KCurrent report2026-10-23SEC
2026-10-234Statement of changes in beneficial ownership of securities2026-10-21SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-258-KCurrent report2026-09-22SEC
2026-09-16SCHEDULE 13D/ASEC
2026-09-158-KCurrent report2026-09-09SEC
2026-09-148-KCurrent report2026-09-11SEC
2026-09-09EFFECTEffectiveness filing by commission orderSEC
2026-09-09S-3/ASEC
2026-09-08S-3/ASEC
2026-09-04SCHEDULE 13DSEC
2026-09-028-KCurrent report2026-09-02SEC
2026-09-028-KCurrent report2026-08-27SEC
2026-08-28S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-248-KCurrent report2026-08-19SEC
2026-08-21S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-078-KCurrent report2026-08-06SEC
2026-07-218-KCurrent report2026-07-17SEC
2026-07-17EFFECTEffectiveness filing by commission orderSEC
2026-07-10S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-06-188-KCurrent report2026-06-17SEC
2026-06-108-KCurrent report2026-06-07SEC
2026-06-09424B5SEC
2026-06-05424B5SEC
2026-06-02DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-17SEC
2026-05-228-KCurrent report2026-05-21SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-117.00K100

Institutional holders

Manager% owned
Lagoda Investment Management, L.P.16.25%
LUMINUS MANAGEMENT LLC1.75%
VANGUARD CAPITAL MANAGEMENT LLC0.57%
Wealthspire Advisors, LLC0.50%
STATE STREET CORP0.38%
Quadrant Private Wealth Management, LLC0.30%
XTX Topco Ltd0.28%
VANGUARD FIDUCIARY TRUST CO0.28%
Miller Financial Services LLC0.25%
BlackRock, Inc.0.25%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.57%
Fidelity Extended Market Index Fund0.25%
Fidelity Total Market Index Fund0.05%
Fidelity Series Total Market Index Fund0.04%
Total Stock Market Index Trust0.01%

OakChart. VNRX. Cached 15 minutes.